Assessing the benefit-risk for new drugs: are the FDA's Endocrinologic and Metabolic Drugs Advisory Committee and the Division of Metabolism and Endocrinology Products in sync?

Diabetes Care. 2013 Jul;36(7):1823-6. doi: 10.2337/dc13-0891. Epub 2013 May 21.

Author

Affiliation

¹ Department of Medicine, Harbor-UCLA Medical Center, Torrance, California, USA. ebrass@ucla.edu

No abstract available

MeSH terms

Advisory Committees
Drug Approval
Humans
Risk Assessment*
United States
United States Food and Drug Administration*